DIRS.INFO The most relevant business & tech news

☆ Danaher shares jump 7% as the turnaround in biotech spending finally arrives
▼ + stars: | 2024-04-23 | by ( Zev Fima | ) www.cnbc.com time to read: +8 min

Shares of Danaher popped more than 7% on Tuesday after the life sciences company delivered beats across its three main businesses — a sign the long-awaited turnaround in the biotech industry is finally here. Danaher Why we own it : Danaher is a best-in-class life sciences and diagnostics company, with a management team who have proven time and again their ability to find new ways to grow. The turnaround is now in effect, with bioprocessing orders up on a sequential basis. Within the segment, bioprocessing sales fell a "high teens" percentage, while discovery and medical declined 20% year over year. Diagnostics sales advanced 7.5% on a core basis to $2.53 billion.

Persons: Danaher, Blair, Beckman Coulter, Jim Cramer's, Jim Cramer, Jim, Igor Golovnov Organizations: LSEG, Bloomberg, Biotechnology, Management, CNBC, Getty Locations: bioprocessing, China, North America, Europe

☆ Danaher shares hit a 1-year high after earnings and we're increasing our price target
▼ + stars: | 2024-01-30 | by ( Zev Fima | ) www.cnbc.com time to read: +10 min

DHR 1Y mountain Danaher 1 year Shares of Danaher rose as much as 5% to a 52-week high of $245.40 each. Core sales, not shown on the table, were down 22.5%. Core sales were down 4% year over year as strength from academic and life science research customers was more than offset by weakness from pharma and biopharma customers. Core sales fell about the same as strength in clinical diagnostics, driven by Beckman Coulter Diagnostics was more than offset by lower respiratory revenue at Cepheid. In this photo illustration, Danaher Corporation logo is seen displayed on a smartphone and PC screen.

Persons: we've, Danaher, Beckman Coulter, Jim Cramer's, Jim Cramer, Jim, Pavlo Gonchar Organizations: Revenue, LSEG, JPMorgan Healthcare, Sciences, Diagnostics, Biotechnology, Management, pharma, Beckman Coulter Diagnostics, CNBC, Getty Locations: Danaher, China, Biotechnology, North America, Europe, Asia, Pacific, Cepheid

☆ Danaher cut its outlook for 2023, but we're maintaining our rating — here's why
▼ + stars: | 2023-07-25 | by ( Zev Fima | ) www.cnbc.com time to read: +9 min

Life sciences and medical diagnostics company Danaher (DHR) delivered a second-quarter earnings beat on Tuesday, but lowered its outlook for the year. When excluding the impact of Covid-related tests and products, Danaher realized base-business core sales growth of 2%. As a result, management was once again forced to downwardly revise their sales growth outlook for the year. We predict a bioprocessing bottom this year, early next year at the very latest, setting us for a rebound in organic revenue growth. This updated outlook represents a downward revision from the high-single-digit percentage decline previously expected on a core basis and the mid-single-digit percentage growth previously expected for the base business.

Persons: Danaher, Cash, Bioprocessing, That's, Sartorius, Cepheid, Jim Cramer's, Jim Cramer, Jim, Marisol Darge, Robert McCabe, Hyoung Chang Organizations: Revenue, Management, Wall, Biotechnology, pharma, CNBC, Kaiser Permanente Arapahoe Medical, Getty Locations: DHR, China, Base, Centennial , Colorado, Denver

☆ 2 of our stocks get nice pops. Here's the news and what we think
▼ + stars: | 2023-01-10 | by ( Zev Fima | ) www.cnbc.com time to read: +6 min

DHR 1Y mountain Danaher's 1 year stock performance Danaher is set to present at the JPMorgan Healthcare Conference on Tuesday afternoon. Now, management sees core sales growth up in the high single-digit range. In addition to the core revenue growth revision, management is now factoring in no growth coming from Covid-related testing. STZ 1Y mountain Constellation Brands 1-year stock performance;. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade.

☆ Danaher shares slide after knockout quarter. Here's why it's a buying opportunity
▼ + stars: | 2022-10-20 | by ( Zev Fima | ) www.cnbc.com time to read: +8 min

That trend is expected to continue and result in high-single-digit core revenue growth for the bioprocessing business for the full year. Driving the gains was 30% core revenue growth at Cepheid as the businesses respiratory testing revenue of about $875 million exceeded management's expectations of roughly $325 million. Guidance Management expects overall core revenue growth to be flat to down low-single-digits for the fourth quarter. For the full year 2022, management continues to forecast base business core revenue growth in the high-single-digit percent range. That's better than the 5.9% full-year core revenue growth expected on the Street.

☆ We're using this rally to make a few trades in the portfolio: one sale, two buys
▼ + stars: | 2022-10-18 | by ( Jeff Marks | ) www.cnbc.com time to read: +6 min

We're buying 20 shares of Danaher (DHR) at roughly $263.99 and 40 shares of Estee Lauder (EL) at roughly $217.05. Estee Lauder We are taking some of that MRVL cash to add to our newest position Estee Lauder . When the pandemic hit and department stores temporarily closed their doors, Estee Lauder pivoted quickly and built direct-to-consumer channels like e-commerce. This shift has allowed Estee Lauder to recapture some lost market share and improve its operating margin outlook. Over the last three years, Estee Lauder has expanded its operating margins by 220 basis points.

☆ We're buying more shares of two companies, stepping off the sidelines in this down market
▼ + stars: | 2022-09-20 | by ( Jim Cramer | ) www.cnbc.com time to read: +5 min

We're buying 25 shares of Danaher (DHR) at roughly $272.79 each. We're also buying 100 shares of TJX Companies (TJX) at roughly $63.04 each. Following Tuesday's trade, the Trust will down 950 shares of TJX, increasing its weighting in the portfolio to 2.13% from 1.91%. We're adding to our position in Danaher and buying back 25 shares we previously sold at higher levels. Danaher shares have fallen about 3.5%, or $10, since the company made these two announcements last Wednesday after the closing bell, compared to a roughly 2.9% decline in the S & P 500 .

☆ Danaher's decision to spin off its water business is a win-win for long-term investors
▼ + stars: | 2022-09-15 | by ( Zev Fima | ) www.cnbc.com time to read: +5 min

Danaher 's (DHR) announcement this week that it will spin off its growing water business is a big win for shareholders — including us at the Club. In both cases, after an initial growth hit due to the divestitures, we saw a notable sales growth acceleration once these slower growth business were on their own. More good news: Danaher's management team said 2022 core revenue growth is expected to be above the prior guidance range thanks higher-than-anticipated respiratory testing revenue at Cepheid. Base business core revenue growth is still expected to be up in the high-single-digit range. Whereas, they think EAS has a longer-term core revenue growth profile in the mid-single-digit range.

Search resuls for: "Cepheid"

8 mentions found